Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pdpSC18
- Development stage
- Phase 1
- Lead developer
- Pfizer
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intramuscular
01
Overview
pdpSC18 is a therapeutic DNA plasmid vaccine developed by PowderMed (later acquired by Pfizer) for the treatment of chronic hepatitis B infection. The vaccine is designed to be administered via the PowderJect ND10 delivery system, which utilizes Particle Mediated Epidermal Delivery (PMED) technology. This "gene gun" approach delivers DNA-coated gold microparticles directly into the epidermal layer of the skin, where the DNA is taken up by cells and expressed to elicit a cellular and humoral immune response against the hepatitis B virus (HBV). The vaccine specifically targets HBV antigens, such as the surface antigen (HBsAg) and core antigen (HBcAg), with the goal of breaking immune tolerance in chronic carriers and stimulating T-cell mediated viral clearance. Development of the program was discontinued following Pfizer's acquisition of PowderMed and a subsequent shift in their vaccine strategy.
- Other names
- PowderMed HBV DNA vaccine
02
Targets
HBc (Hepatitis B virus core protein)HBsAg (Hepatitis B surface antigen)
Beyond the preview
Go deeper on pdpSC18.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pdpSC18.